Nubeqa is a medicine used to treat men with prostate cancer. It is used when the cancer is castration-resistant (worsens despite treatment to lower testosterone levels, including surgical removal of the testes) and is at high risk of metastasis (spreading to other parts of the body). It is also used when the cancer has spread to other parts of the body but responds to treatment that lowers testosterone levels (hormone sensitive). It is used in combination with docetaxel (another cancer medicine) and a treatment called androgen deprivation therapy (treatment to lower male sex hormones). Nubeqa contains the active substance darolutamide.
Therapeutic Indication
### Therapeutic indication NUBEQA is indicated for the treatment of adult men with \- non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1). \- metastatic hormone sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1).
Therapeutic Area (MeSH)
ATC Code
L02BB
ATC Item
抗雄激素类
Pharmacotherapeutic Group
Endocrine therapy
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| darolutamide | N/A | 达洛鲁胺 |
EMA Name
Nubeqa
Medicine Name
Nubeqa
Aliases
N/ANo risk management plan link.
